Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin?

Neuroscience and Biobehavioral Reviews

Volumn 38, Issue 1, 2014, Pages 60-71

  Vriend, Chris ^a,b   Pattij, Tommy ^a,b   Van Der Werf, Ysbrand D ^a,b,c   Voorn, Pieter ^a   Booij, Jan ^d   Rutten, Sonja ^a   Berendse, Henk W ^a,b   Van Den Heuvel, Odile A ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Animal studies; Brain imaging; Depression; Dopamine; Impulse control disorders; Non motor symptoms; Parkinson's disease

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; PLACEBO; PRAMIPEXOLE;

ANTIDEPRESSANT ACTIVITY; APATHY; BRAIN DYSFUNCTION; BRAIN REGION; CORPUS STRIATUM; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; HUMAN; IMPULSE CONTROL DISORDER; MOTIVATION; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REVIEW; REWARD; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTITUTION THERAPY; THALAMOCORTICAL TRACT;

ANIMAL STUDIES; BRAIN IMAGING; DEPRESSION; DOPAMINE; IMPULSE CONTROL DISORDERS; NON-MOTOR SYMPTOMS; PARKINSON'S DISEASE;

ANIMALS; BRAIN; DEPRESSIVE DISORDER; DOPAMINE; DOPAMINE AGENTS; HUMANS; IMPULSE CONTROL DISORDERS; MODELS, NEUROLOGICAL; PARKINSON DISEASE;

EID: 84888081901     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.11.001     Document Type: Review

References (136)

1. Aarsland D., Pahlhagen S., Ballard C.G., Ehrt U., Svenningsson P. Depression in Parkinson disease-epidemiology, mechanisms and management. Nat. Rev. Neurol. 2012, 8:35-47.
2. Aarts E., Helmich R.C., Janssen M.J., Oyen W.J., Bloem B.R., Cools R. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. Neuroimage 2012, 59:3339-3346.
3. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, Amer Psychiatric Pub Inc, Washington, DC. 4th ed.
5. Antonini A., Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009, 32:475-488.
6. Baarendse P.J., Vanderschuren L.J. Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats. Psychopharmacology (Berl.) 2012, 219:313-326.
7. Baarendse P.J., Winstanley C.A., Vanderschuren L.J. Simultaneous blockade of dopamine and noradrenaline reuptake promotes disadvantageous decision making in a rat gambling task. Psychopharmacology (Berl.) 2013, 225:719-731.
8. Ballanger B., Klinger H., Eche J., Lerond J., Vallet A.E., Le Bars D., Tremblay L., Sgambato-Faure V., Broussolle E., Thobois S. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov. Disord. 2012, 27:84-89.
9. Barbelivien A., Billy E., Lazarus C., Kelche C., Majchrzak M. Rats with different profiles of impulsive choice behavior exhibit differences in responses to caffeine and d-amphetamine and in medial prefrontal cortex 5-HT utilization. Behav. Brain Res. 2008, 187:273-283.
10. Barone P., Poewe W., Albrecht S., Debieuvre C., Massey D., Rascol O., Tolosa E., Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9:573-580.
11. Bjorklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30:194-202.
12. Bodi N., Keri S., Nagy H., Moustafa A., Myers C.E., Daw N., Dibo G., Takats A., Bereczki D., Gluck M.A. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009, 132:2385-2395.
13. 11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009, 132:1366-1375.
14. Booij J., Tissingh G., Winogrodzka A., van Royen E.A. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur. J. Nucl. Med. 1999, 26:171-182.
15. Breuer M.E., Groenink L., Oosting R.S., Buerger E., Korte M., Ferger B., Olivier B. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur. J. Pharmacol. 2009, 616:134-140.
16. 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J. Neurol. Sci. 1999, 166:141-151.
17. Buckholtz J.W., Treadway M.T., Cowan R.L., Woodward N.D., Li R., Ansari M.S., Baldwin R.M., Schwartzman A.N., Shelby E.S., Smith C.E., Kessler R.M., Zald D.H. Dopaminergic network differences in human impulsivity. Science 2010, 329:532.
18. Cardoso E.F., Maia F.M., Fregni F., Myczkowski M.L., Melo L.M., Sato J.R., Marcolin M.A., Rigonatti S.P., Cruz A.C., Barbosa E.R., Amaro E. Depression in Parkinson's disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. Neuroimage 2009, 47:467-472.
19. Carlson P.J., Singh J.B., Zarate C.A., Drevets W.C., Manji H.K. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 2006, 3:22-41.
20. Cilia R., Cho S.S., van Eimeren T., Marotta G., Siri C., Ko J.H., Pellecchia G., Pezzoli G., Antonini A., Strafella A.P. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov. Disord. 2011, 26:225-233.
21. Cilia R., Ko J.H., Cho S.S., van Eimeren T., Marotta G., Pellecchia G., Pezzoli G., Antonini A., Strafella A.P. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol. Dis. 2010, 39:98-104.
22. Cilia R., Siri C., Marotta G., Isaias I.U., De Gaspari D., Canesi M., Pezzoli G., Antonini A. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch. Neurol. 2008, 65:1604-1611.
23. Claassen D.O., van den Wildenberg W.P., Ridderinkhof K.R., Jessup C.K., Harrison M.B., Wooten G.F., Wylie S.A. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav. Neurosci. 2011, 125:492-500.
24. Cole B.J., Robbins T.W. Amphetamine impairs the discriminative performance of rats with dorsal noradrenergic bundle lesions on a 5-choice serial reaction time task: new evidence for central dopaminergic-noradrenergic interactions. Psychopharmacology (Berl.) 1987, 91:458-466.
25. Cole B.J., Robbins T.W. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi on performance of a 5-choice serial reaction time task in rats: implications for theories of selective attention and arousal. Behav. Brain Res. 1989, 33:165-179.
26. Dalley J.W., Fryer T.D., Brichard L., Robinson E.S., Theobald D.E., Laane K., Pena Y., Murphy E.R., Shah Y., Probst K., Abakumova I., Aigbirhio F.I., Richards H.K., Hong Y., Baron J.C., Everitt B.J., Robbins T.W. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007, 315:1267-1270.
27. Dalley J.W., Roiser J.P. Dopamine, serotonin and impulsivity. Neuroscience 2012, 215:42-58.
28. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
29. Djamshidian A., Averbeck B.B., Lees A.J., O'Sullivan S.S. Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. J. Neurol. Sci. 2011, 310:183-188.
30. Drui G., Carnicella S., Carcenac C., Favier M., Bertrand A., Boulet S., Savasta M. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol. Psychiatry 2013, advance online publication: Feb 12, 2013.
31. Eagle D.M., Wong J.C., Allan M.E., Mar A.C., Theobald D.E., Robbins T.W. Contrasting roles for dopamine D1 and D2 receptor subtypes in the dorsomedial striatum but not the nucleus accumbens core during behavioral inhibition in the stop-signal task in rats. J. Neurosci. 2011, 31:7349-7356.
32. Engeln M., Fasano S., Ahmed S.H., Cador M., Baekelandt V., Bezard E., Fernagut P.O. l-dopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann. Neurol. 2013, published online first: Aug 6, 2013.
33. Evans A.H., Strafella A.P., Weintraub D., Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov. Disord. 2009, 24:1561-1570.
34. Feldmann A., Illes Z., Kosztolanyi P., Illes E., Mike A., Kover F., Balas I., Kovacs N., Nagy F. Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study. Mov. Disord. 2008, 23:42-46.
35. Felicio A.C., Moriyama T.S., Godeiro-Junior C., Shih M.C., Hoexter M.Q., Borges V., Silva S.M., Amaro-Junior E., Andrade L.A., Ferraz H.B., Bressan R.A. Higher dopamine transporter density in Parkinson's disease patients with depression. Psychopharmacology (Berl.) 2010, 211:27-31.
36. Frank M.J., Seeberger L.C., O'Reilly R.C. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004, 306:1940-1943.
37. Friedman A., Friedman Y., Dremencov E., Yadid G. VTA dopamine neuron bursting is altered in an animal model of depression and corrected by desipramine. J. Mol. Neurosci. 2008, 34:201-209.
38. Frisina P.G., Haroutunian V., Libow L.S. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:144-148.
39. Frosini D., Pesaresi I., Cosottini M., Belmonte G., Rossi C., Dell'Osso L., Murri L., Bonuccelli U., Ceravolo R. Parkinson's disease and pathological gambling: results from a functional MRI study. Mov. Disord. 2010, 25:2449-2453.
40. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 2002, 22:5042-5054.
41. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34:441-466.
42. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J. Neural Transm. 2003, 110:1119-1127.
43. Groenewegen H.J., Trimble M. The ventral striatum as an interface between the limbic and motor systems. CNS Spectr. 2007, 12:887-892.
44. Groenewegen H.J., Uylings H.B.M. Organization of prefrontal-striatal connections. Handbook of Basal Ganglia Structure and Function 2010, Academic Press, San Diego, CA. H. Steiner, K.Y. Tseng (Eds.).
45. Haber S.N., Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 2010, 35:4-26.
46. Haber S.N., McFarland N.R. The concept of the ventral striatum in nonhuman primates. Ann. N.Y. Acad. Sci. 1999, 877:33-48.
47. Haber S.N., Ryoo H., Cox C., Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 1995, 362:400-410.
48. Hesse S., Meyer P.M., Strecker K., Barthel H., Wegner F., Oehlwein C., Isaias I.U., Schwarz J., Sabri O. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:428-435.
49. Holman A.J. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J. Gambl. Stud. 2009, 25:425-431.
50. Johnson P.S., Madden G.J., Brewer A.T., Pinkston J.W., Fowler S.C. Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats. Psychopharmacology (Berl.) 2011, 213:11-18.
51. Joutsa J., Johansson J., Niemela S., Ollikainen A., Hirvonen M.M., Piepponen P., Arponen E., Alho H., Voon V., Rinne J.O., Hietala J., Kaasinen V. Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage 2012, 60:1992-1999.
52. 18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov. Disord. 2012, 27:778-782.
53. Joutsa J., Martikainen K., Vahlberg T., Kaasinen V. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18:1079-1083.
54. Joutsa J., Martikainen K., Vahlberg T., Voon V., Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18:155-160.
55. Kano O., Ikeda K., Cridebring D., Takazawa T., Yoshii Y., Iwasaki Y. Neurobiology of depression and anxiety in Parkinson's disease. Parkinsons Dis. 2011, 2011:143547.
56. Kirsch-Darrow L., Marsiske M., Okun M.S., Bauer R., Bowers D. Apathy and depression: separate factors in Parkinson's disease. J. Int. Neuropsychol. Soc. 2011, 17:1058-1066.
57. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
58. Kobayakawa M., Koyama S., Mimura M., Kawamura M. Decision making in Parkinson's disease: analysis of behavioral and physiological patterns in the Iowa gambling task. Mov. Disord. 2008, 23:547-552.
59. Koolschijn P.C., van Haren N.E., Lensvelt-Mulders G.J., Hulshoff Pol H.E., Kahn R.S. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum. Brain Mapp. 2009, 30:3719-3735.
60. Kostic V.S., Agosta F., Petrovic I., Galantucci S., Spica V., Jecmenica-Lukic M., Filippi M. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 2010, 75:857-863.
61. Lee J.Y., Lee E.K., Park S.S., Lim J.Y., Kim H.J., Kim J.S., Jeon B.S. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov. Disord. 2009, 24:1803-1810.
62. Leentjens A.F., Van den Akker M., Metsemakers J.F., Lousberg R., Verhey F.R. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov. Disord. 2003, 18:414-418.
63. Leroi I., Andrews M., McDonald K., Harbishettar V., Elliott R., Byrne E.J., Burns A. Apathy and impulse control disorders in Parkinson's disease: a direct comparison. Parkinsonism Relat. Disord. 2012, 18:198-203.
64. Lyons K.E., Pahwa R. The impact and management of nonmotor symptoms of Parkinson's disease. Am. J. Manag. Care 2011, 17(Suppl. 12):S308L 314.
65. Maricle R.A., Nutt J.G., Valentine R.J., Carter J.H. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995, 45:1757-1760.
66. Marin R.S. Apathy: a neuropsychiatric syndrome. J. Neuropsychiatry Clin. Neurosci. 1991, 3:243-254.
67. Mayberg H.S., Starkstein S.E., Sadzot B., Preziosi T., Andrezejewski P.L., Dannals R.F., Wagner H.N., Robinson R.G. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann. Neurol. 1990, 28:57-64.
68. Mentis M.J., McIntosh A.R., Perrine K., Dhawan V., Berlin B., Feigin A., Edwards C., Mattis P., Eidelberg D. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am. J. Psychiatry 2002, 159:746-754.
69. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Buyske S., Bienfait K., Dicke A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72:886-892.
70. Muscat R., Papp M., Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol. Psychiatry 1992, 31:937-946.
71. Nader M.A., Morgan D., Gage H.D., Nader S.H., Calhoun T.L., Buchheimer N., Ehrenkaufer R., Mach R.H. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat. Neurosci. 2006, 9:1050-1056.
72. Neve K.A., Seamans J.K., Trantham-Davidson H. Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 2004, 24:165-205.
73. O'Sullivan S.S., Wu K., Politis M., Lawrence A.D., Evans A.H., Bose S.K., Djamshidian A., Lees A.J., Piccini P. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011, 134:969-978.
74. Pagonabarraga J., Garcia-Sanchez C., Llebaria G., Pascual-Sedano B., Gironell A., Kulisevsky J. Controlled study of decision-making and cognitive impairment in Parkinson's disease. Mov. Disord. 2007, 22:1430-1435.
75. Pattij T., Janssen M.C., Vanderschuren L.J., Schoffelmeer A.N., van Gaalen M.M. Involvement of dopamine D1 and D2 receptors in the nucleus accumbens core and shell in inhibitory response control. Psychopharmacology (Berl.) 2007, 191:587-598.
76. Pattij T., Vanderschuren L.J. The neuropharmacology of impulsive behaviour. Trends Pharmacol. Sci. 2008, 29:192-199.
77. Pezze M.A., Dalley J.W., Robbins T.W. Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology 2007, 32:273-283.
78. Pizzagalli D.A., Holmes A.J., Dillon D.G., Goetz E.L., Birk J.L., Bogdan R., Dougherty D.D., Iosifescu D.V., Rauch S.L., Fava M. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am. J. Psychiatry 2009, 166:702-710.
79. Politis M., Loane C., Wu K., O'Sullivan S.S., Woodhead Z., Kiferle L., Lawrence A.D., Lees A.J., Piccini P. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain 2013, 136:400-411.
80. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Oertel W.H., Bjorklund A., Lindvall O., Piccini P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci. Transl. Med. 2012, 4:128ra141.
81. Politis M., Wu K., Loane C., Turkheimer F.E., Molloy S., Brooks D.J., Piccini P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010, 75:1920-1927.
82. Pontone G., Williams J.R., Bassett S.S., Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006, 67:1258-1261.
83. Price J.L., Drevets W.C. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn. Sci. 2012, 16:61-71.
84. 2+ current modulation in neostriatal neurons. Neuroscience 2009, 164:345-350.
85. Prieto G.A., Perez-Burgos A., Palomero-Rivero M., Galarraga E., Drucker-Colin R., Bargas J. Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on Ca V 2.1 channels via PIP2 depletion. J. Neurophysiol. 2011, 105:2260-2274.
86. Rao H., Mamikonyan E., Detre J.A., Siderowf A.D., Stern M.B., Potenza M.N., Weintraub D. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov. Disord. 2010, 25:1660-1669.
87. 11C] FLB-457 and PET study. Neurobiol. Dis. 2012, 48:519-525.
88. Reijnders J.S., Scholtissen B., Weber W.E., Aalten P., Verhey F.R., Leentjens A.F. Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry. Mov. Disord. 2010, 25:2318-2325.
89. Rektorova I., Srovnalova H., Kubikova R., Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. Mov. Disord. 2008, 23:1580-1587.
90. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
91. Richard I.H., McDermott M.P., Kurlan R., Lyness J.M., Como P.G., Pearson N., Factor S.A., Juncos J., Serrano Ramos C., Brodsky M., Manning C., Marsh L., Shulman L., Fernandez H.H., Black K.J., Panisset M., Christine C.W., Jiang W., Singer C., Horn S., Pfeiffer R., Rottenberg D., Slevin J., Elmer L., Press D., Hyson H.C., McDonald W. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012, 78:1229-1236.
92. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J. Neurol. Neurosurg. Psychiatry 2005, 76(Suppl. 1):i48-i52.
93. Ring H.A., Bench C.J., Trimble M.R., Brooks D.J., Frackowiak R.S., Dolan R.J. Depression in Parkinson's disease. A positron emission study. Br. J. Psychiatry 1994, 165:333-339.
94. Robert G., Le Jeune F., Lozachmeur C., Drapier S., Dondaine T., Peron J., Travers D., Sauleau P., Millet B., Verin M., Drapier D. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology 2012, 79:1155-1160.
95. Rocha F.L., Murad M.G., Stumpf B.P., Hara C., Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J. Psychopharmacol. (Oxford, England) 2013, 27:417-423.
96. Rokosik S.L., Napier T.C. Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls. Neuropsychopharmacology 2012, 37:1397-1408.
97. Santamaria J., Tolosa E., Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986, 36:1130-1133.
98. Scherfler C., Schwarz J., Antonini A., Grosset D., Valldeoriola F., Marek K., Oertel W., Tolosa E., Lees A.J., Poewe W. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov. Disord. 2007, 22:1229-1238.
99. Schrag A., Jahanshahi M., Quinn N.P. What contributes to depression in Parkinson's disease?. Psychol. Med. 2001, 31:65-73.
100. Schuurman A.G., van den Akker M., Ensinck K.T., Metsemakers J.F., Knottnerus J.A., Leentjens A.F., Buntinx F. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002, 58:1501-1504.
101. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
102. Shiba M., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., Rocca W.A. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov. Disord. 2000, 15:669-677.
103. Skidmore F.M., Yang M., Baxter L., von Deneen K., Collingwood J., He G., Tandon R., Korenkevych D., Savenkov A., Heilman K.M., Gold M., Liu Y. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage 2013, 81:484-495.
104. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
105. 123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006, 129:1188-1193.
106. Starkstein S.E., Leentjens A.F. The nosological position of apathy in clinical practice. J. Neurol. Neurosurg. Psychiatry 2008, 79:1088-1092.
107. 11C] raclopride PET study. Brain 2009, 132:1376-1385.
108. Storch A., Schneider C.B., Wolz M., Sturwald Y., Nebe A., Odin P., Mahler A., Fuchs G., Jost W.H., Chaudhuri K.R., Koch R., Reichmann H., Ebersbach G. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013, published online before print: Jan 30, 2013.
109. Surmeier D.J., Ding J., Day M., Wang Z., Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007, 30:228-235.
110. Tan S.K., Hartung H., Sharp T., Temel Y. Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus?. Neuropharmacology 2011, 61:387-399.
111. Thobois S., Ardouin C., Lhommee E., Klinger H., Lagrange C., Xie J., Fraix V., Coelho Braga M.C., Hassani R., Kistner A., Juphard A., Seigneuret E., Chabardes S., Mertens P., Polo G., Reilhac A., Costes N., LeBars D., Savasta M., Tremblay L., Quesada J.L., Bosson J.L., Benabid A.L., Broussolle E., Pollak P., Krack P. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133:1111-1127.
112. van den Heuvel O.A., van der Werf Y.D., Verhoef K.M., de Wit S., Berendse H.W., Wolters E., Veltman D.J., Groenewegen H.J. Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. J. Neurol. Sci. 2010, 289:55-59.
113. van Eimeren T., Ballanger B., Pellecchia G., Miyasaki J.M., Lang A.E., Strafella A.P. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34:2758-2766.
114. van Eimeren T., Pellecchia G., Cilia R., Ballanger B., Steeves T.D., Houle S., Miyasaki J.M., Zurowski M., Lang A.E., Strafella A.P. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010, 75:1711-1716.
115. van Gaalen M.M., Brueggeman R.J., Bronius P.F., Schoffelmeer A.N., Vanderschuren L.J. Behavioral disinhibition requires dopamine receptor activation. Psychopharmacology (Berl.) 2006, 187:73-85.
116. van Gaalen M.M., van Koten R., Schoffelmeer A.N., Vanderschuren L.J. Critical involvement of dopaminergic neurotransmission in impulsive decision making. Biol. Psychiatry 2006, 60:66-73.
117. van Mierlo T., Chung C., Foncke E.M.J., Berendse H.W., van den Heuvel O.A. Hippocampal Volume Related to Depressive Symptoms in Parkinson's Disease-A Voxel Based Morphometry Study 2013, VU University Medical Center, Amsterdam, The Netherlands, (in preparation).
118. Volkow N.D., Wang G.J., Fowler J.S., Thanos P.P., Logan J., Gatley S.J., Gifford A., Ding Y.S., Wong C., Pappas N. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 2002, 46:79-82.
119. Volkow N.D., Wang G.J., Telang F., Fowler J.S., Thanos P.K., Logan J., Alexoff D., Ding Y.S., Wong C., Ma Y., Pradhan K. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage 2008, 42:1537-1543.
120. Voon V., Fernagut P.O., Wickens J., Baunez C., Rodriguez M., Pavon N., Juncos J.L., Obeso J.A., Bezard E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009, 8:1140-1149.
121. Voon V., Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol. 2007, 64:1089-1096.
122. Voon V., Pessiglione M., Brezing C., Gallea C., Fernandez H.H., Dolan R.J., Hallett M. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010, 65:135-142.
123. Voon V., Gao J., Brezing C., Symmonds M., Ekanayake V., Fernandez H., Dolan R.J., Hallett M. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011, 134:1438-1446.
124. Voon V., Mehta A.R., Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Curr. Opin. Neurol. 2011, 24:324-330.
125. Voon V., Rizos A., Chakravartty R., et al. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J. Neurol. Neurosurg. Psychiatry 2013, published Online First: July 30.
126. Voon V., Schoerling A., Wenzel S., Ekanayake V., Reiff J., Trenkwalder C., Sixel-Doring F. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011, 11:117.
127. Voon V., Sohr M., Lang A.E., Potenza M.N., Siderowf A.D., Whetteckey J., Weintraub D., Wunderlich G.R., Stacy M. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann. Neurol. 2011, 69:986-996.
128. Vriend C., Nordbeck A.H., Booij J., Van der Werf Y.D., Pattij T., Voorn P., Raijmakers P., Foncke E.M.J., van de Giessen E., Berendse H.W., Van den Heuvel O.A. Reduced Dopamine Transporter Binding Predates Impulse Control Disorders in Parkinson's Disease 2013, VU University Medical Center, Amsterdam, The Netherlands, (submitted for publication).
129. 123I]FP-CIT binding in the caudate nucleus. J. Neurol. Neurosurg. Psychiatry 2013, Online available only.
130. Walter U., Hoeppner J., Prudente-Morrissey L., Horowski S., Herpertz S.C., Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007, 130:1799-1807.
131. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann. Neurol. 2008, 64(Suppl. 2):S93L 100.
132. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., Whetteckey J., Wunderlich G.R., Lang A.E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010, 67:589-595.
133. Weintraub D., Newberg A.B., Cary M.S., Siderowf A.D., Moberg P.J., Kleiner-Fisman G., Duda J.E., Stern M.B., Mozley D., Katz I.R. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J. Nucl. Med. 2005, 46:227-232.
134. Winstanley C.A. The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br. J. Pharmacol. 2011, 164:1301-1321.
135. Wise R.A. Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. Trends Neurosci. 2009, 32:517-524.
136. Wu K., Politis M., Piccini P. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad. Med. J. 2009, 85:590-596.